InsiderTrades.com logo
Kevin Judice net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Kevin Judice Biography and Net Worth

Co-Founder & CEO of DICE Therapeutics

Kevin Judice currently serves as the co-founder and CEO of DICE Therapeutics. Prior to DICE, he co-founded Achaogen, Inc., where, as the first employee, he was the chief scientific officer and CEO. During his seven-year tenure at Achaogen, Kevin oversaw three rounds of venture financing, steered its growth to 65 full-time employees and established collaborations with DARPA, NIAID, DTRA and BARDA.

Prior to Achaogen, he ran medicinal chemistry at Genentech. In the late ‘90s, he was one of the first employees and served as the vice president of chemistry at Theravance, where he led the discovery of Vibativ®.

Kevin holds a Ph.D. in organic chemistry from the University of California Los Angeles with Nobel Laureate Donald J. Cram, then did his postdoctoral fellowship at the University of California Berkeley in the laboratories of Peter G. Schultz. He received his B.S. in chemistry from Texas A&M University. Kevin is also a Henry Crown fellow at the Aspen Institute.

What is Kevin Judice's net worth?

The estimated net worth of Kevin Judice is at least $38.03 million as of May 3rd, 2023. Dr. Judice owns 799,685 shares of DICE Therapeutics stock worth more than $38,025,022 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Judice may own. Additionally, Dr. Judice receives an annual salary of $840,000.00 as Co-Founder & CEO at DICE Therapeutics. Learn More about Kevin Judice's net worth.

How old is Kevin Judice?

Dr. Judice is currently 59 years old. There are 2 older executives and no younger executives at DICE Therapeutics. Learn More on Kevin Judice's age.

What is Kevin Judice's salary?

As the Co-Founder & CEO of DICE Therapeutics, Inc., Dr. Judice earns $840,000.00 per year. Learn More on Kevin Judice's salary.

How do I contact Kevin Judice?

The corporate mailing address for Dr. Judice and other DICE Therapeutics executives is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. DICE Therapeutics can also be reached via phone at 650-566-1420 and via email at [email protected]. Learn More on Kevin Judice's contact information.

Has Kevin Judice been buying or selling shares of DICE Therapeutics?

Kevin Judice has not been actively trading shares of DICE Therapeutics during the last ninety days. Most recently, Kevin Judice sold 13,698 shares of the business's stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $36.50, for a transaction totalling $499,977.00. Following the completion of the sale, the chief executive officer now directly owns 799,685 shares of the company's stock, valued at $29,188,502.50. Learn More on Kevin Judice's trading history.

Who are DICE Therapeutics' active insiders?

DICE Therapeutics' insider roster includes Kevin Judice (Co-Founder & CEO), Richard Scheller (Chairman of the Board), and James Scopa (Director). Learn More on DICE Therapeutics' active insiders.

Kevin Judice Insider Trading History at DICE Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2023Sell13,698$36.50$499,977.00799,685View SEC Filing Icon  
See Full Table

Kevin Judice Buying and Selling Activity at DICE Therapeutics

This chart shows Kevin Judice's buying and selling at DICE Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DICE Therapeutics Company Overview

DICE Therapeutics logo
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $47.55
Low: $47.55
High: $47.55

50 Day Range

MA: $47.31
Low: $46.62
High: $47.55

2 Week Range

Now: $47.55
Low: $15.08
High: $47.90

Volume

N/A

Average Volume

1,028,719 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03